» Articles » PMID: 37745252

Exosomes As Biomarkers and Therapy in Type 2 Diabetes Mellitus and Associated Complications

Overview
Journal Front Physiol
Date 2023 Sep 25
PMID 37745252
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic disorders worldwide. However, T2DM still remains underdiagnosed and undertreated resulting in poor quality of life and increased morbidity and mortality. Given this ongoing burden, researchers have attempted to locate new therapeutic targets as well as methodologies to identify the disease and its associated complications at an earlier stage. Several studies over the last few decades have identified exosomes, small extracellular vesicles that are released by cells, as pivotal contributors to the pathogenesis of T2DM and its complications. These discoveries suggest the possibility of novel detection and treatment methods. This review provides a comprehensive presentation of exosomes that hold potential as novel biomarkers and therapeutic targets. Additional focus is given to characterizing the role of exosomes in T2DM complications, including diabetic angiopathy, diabetic cardiomyopathy, diabetic nephropathy, diabetic peripheral neuropathy, diabetic retinopathy, and diabetic wound healing. This study reveals that the utilization of exosomes as diagnostic markers and therapies is a realistic possibility for both T2DM and its complications. However, the majority of the current research is limited to animal models, warranting further investigation of exosomes in clinical trials. This review represents the most extensive and up-to-date exploration of exosomes in relation to T2DM and its complications.

Citing Articles

Human studies of the efficacy and safety of stem cells in the treatment of diabetic peripheral neuropathy: a systematic review and meta-analysis.

Alizadeh S, Jahani S, Rezaei Zadeh Rukerd M, Tabrizi R, Masoomi R, Banihashemian S Stem Cell Res Ther. 2024; 15(1):442.

PMID: 39563393 PMC: 11577959. DOI: 10.1186/s13287-024-04033-3.


Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications.

Kurdi H, Lavalle L, Moon J, Hughes D Front Cardiovasc Med. 2024; 11:1420067.

PMID: 38932991 PMC: 11199868. DOI: 10.3389/fcvm.2024.1420067.


Extracellular Vesicles in Metabolic and Vascular Insulin Resistance.

Malin S, Erdbrugger U J Vasc Res. 2024; 61(3):129-141.

PMID: 38615667 PMC: 11149383. DOI: 10.1159/000538197.

References
1.
Wubbolts R, Leckie R, Veenhuizen P, Schwarzmann G, Mobius W, Hoernschemeyer J . Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003; 278(13):10963-72. DOI: 10.1074/jbc.M207550200. View

2.
Tao Y, Wei X, Yue Y, Wang J, Li J, Shen L . Extracellular vesicle-derived AEBP1 mRNA as a novel candidate biomarker for diabetic kidney disease. J Transl Med. 2021; 19(1):326. PMC: 8325821. DOI: 10.1186/s12967-021-03000-3. View

3.
Xing Q, Zhang G, Kang L, Wu J, Chen H, Liu G . The Suppression of Kallistatin on High-Glucose-Induced Proliferation of Retinal Endothelial Cells in Diabetic Retinopathy. Ophthalmic Res. 2016; 57(3):141-149. DOI: 10.1159/000447776. View

4.
Jones A, Danielson K, Benton M, Ziegler O, Shah R, Stubbs R . miRNA Signatures of Insulin Resistance in Obesity. Obesity (Silver Spring). 2017; 25(10):1734-1744. PMC: 5614819. DOI: 10.1002/oby.21950. View

5.
Halkein J, Tabruyn S, Ricke-Hoch M, Haghikia A, Nguyen N, Scherr M . MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013; 123(5):2143-54. PMC: 3638905. DOI: 10.1172/JCI64365. View